ESR1 and triple-negative breast carcinoma: Unlike BRCA2 mutation carriers, who are more likely to develop tumors that are progesterone receptor (PR)- or estrogen receptor (ER)-positive, BRCA1 mutation carriers predominantly develop triple-negative breast cancer (TNBC) (Figure 2b) [21].